Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: A randomized, investigator-blinded trial

British Journal of Dermatology

Volumn 172, Issue 4, 2015, Pages 1103-1110

  Taieb, A ^a   Ortonne, J P ^b   Ruzicka, T ^c   Roszkiewicz, J ^d   Berth Jones, J ^e   Peirone, M H ^f   Jacovella, J ^f  

^a HÔPITAL SAINT ANDRÉ   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c UNIVERSITY OF MUNICH   (Germany)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e Department of Dermatology   (United Kingdom)

^f Galderma R and D   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IVERMECTIN; METRONIDAZOLE; DERMATOLOGICAL AGENT; OINTMENT;

ADULT; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; CREAM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HUMAN; INFLAMMATION; INVESTIGATOR GLOBAL ASSESSMENT; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PARALLEL DESIGN; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ROSACEA; SINGLE BLIND PROCEDURE; SKIN DISEASE ASSESSMENT; SKIN IRRITATION; TREATMENT RESPONSE; ADOLESCENT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; OINTMENT; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IVERMECTIN; MALE; METRONIDAZOLE; MIDDLE AGED; OINTMENTS; PATIENT SATISFACTION; ROSACEA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84926189281     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13408     Document Type: Article

References (24)

1. Chosidow O, Cribier B,. Epidemiology of rosacea: updated data. Ann Dermatol Venereol 2011; 138 (Suppl. 3): S179-83.
2. Berg M, Lidén S,. An epidemiological study of rosacea. Acta Derm Venereol 1989; 69: 419-23.
3. McAleer MA, Fitzpatrick P, Powell FC,. Papulopustular rosacea: prevalence and relationship to photodamage. J Am Acad Dermatol 2010; 63: 33-9.
4. Augustin M, Herberger K, Hintzen S, et al,. Prevalence of skin lesions and need for treatment in a cohort of 90880 workers. Br J Dermatol 2011; 165: 865-73.
5. Wilkin J, Dahl M, Detmar M, et al,. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2002; 46: 584-7.
6. Balkrishnan R, McMichael AJ, Hu JY, et al,. Correlates of health-related quality of life in women with severe facial blemishes. Int J Dermatol 2006; 45: 111-15.
7. Del Rosso JQ, Gallo RL, Tanghetti E, et al,. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis 2013; 91 (Suppl 3): 1-8.
8. Holmes AD,. Potential role of microorganisms in the pathogenesis of rosacea. J Am Acad Dermatol 2013; 69: 1025-32.
9. Pelle MT, Crawford GH, James WD,. Rosacea: II. Therapy. J Am Acad Dermatol 2004; 51: 499-514.
10. van Zuuren EJ, Kramer SF, Carter BR, et al,. Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review. Br J Dermatol 2011; 165: 760-81.
11. Shimose L, Munoz-Price LS,. Diagnosis, prevention, and treatment of scabies. Curr Infect Dis Rep 2013; 15: 426-31.
12. Pariser DM, Meinking TL, Bell M, Ryan WG,. Topical 0.5% ivermectin lotion for treatment of head lice. N Engl J Med 2012; 367: 1687-93.
13. Damian D,. Demodex infestation in a child with leukemia: treatment with ivermectin and permethrin. Int J Dermatol 2003; 42: 724-6.
14. Filho PA, Hazarbassanov RM, Grisolia AB, et al,. The efficacy of oral ivermectin for the treatment of chronic blepharitis in patients tested positive for Demodex spp. Br J Ophthalmol 2011; 95: 893-5.
15. Ci X, Li H, Yu Q, et al,. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam Clin Pharmacol 2009; 23: 449-55.
16. Yanagihara K, Kadoto J, Kohno S,. Diffuse panbronchiolitis- pathophysiology and treatment mechanisms. Int J Antimicrob Agents 2001; 18 (Suppl. 1): S83-7.
17. Ianaro A, Ialenti A, Maffia P, et al,. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292: 156-63.
18. Stein L, Kircik L, Fowler J, et al,. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol 2014; 13: 316-23.
19. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
20. Elewski BE, Draelos Z, Dréno B, et al,. Rosacea-global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 2011; 25: 188-200.
21. Zhang X, Song Y, Ci X, et al,. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res 2008; 57: 524-9.
22. Jain A, Sangal L, Basal E, et al,. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J 2002; 8: 2.
23. Wolstenholme AJ, Rogers AT,. Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics. Parasitology 2005; 131 (Suppl): S85-95.
24. Forton FMN,. Papulopustular rosacea, skin immunity and Demodex: pityriasis folliculorum as a missing link. J Eur Acad Dermatol Venereol 2012; 26: 19-28.